Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
The Pediatric Cancer Research Foundation, a nonproﬁt focused on transforming pediatric cancer care by accelerating research breakthroughs, today announced the 19 recipients of its 2023 research grants.
Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority to no longer require regular blood transfusions.
New animal research is helping explain why at least five people have become HIV-free after receiving a stem cell transplant.
Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology's annual meeting.
Children's Cancer Research Fund has awarded $250,000 to an innovative new approach to treating leukemia – blood cancer – being developed at UVA Cancer Center.
David and Adair Keller started their married life together in 1977 at Camp Lejeune, a military training base on the Atlantic Coast in Jacksonville, North Carolina. David was a Marine Corps field artillery officer then, and they lived together on the base for about six months.
Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow.
The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support collaborative research teams working to discover novel molecular targets to eradicate minimal residual disease in acute myeloid leukemia (AML) and to treat clonal hematopoiesis, a precursor to AML.
Researchers have developed a new method to distinguish between cancerous and healthy stem cells and progenitor cells from samples of patients with acute myeloid leukemia (AML), a disease driven by malignant blood stem cells that have historically been difficult to identify.
Acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes a large number of abnormal blood cells. It is the most common type of acute leukemia in adults.
Despite the promise of new medications that promote cancer cell death in people with acute myeloid leukemia, leukemic cells often adopt features that let them evade the drugs' effects within a year.
Acute myeloid leukemia (AML) is a cancer that affects blood cells in the bone marrow -; the spongy tissue inside certain bones, where new blood cells are made.
Researchers reviewed existing data on tumor-promotive risk factors and their underlying mechanisms.
The scientific foundation needed to work on curing a class of cancer-causing mutations is here, in the form of a tool from St. Jude Children's Research Hospital.
Johns Hopkins Medicine scientists say their 20-year study of more than 200 people with premature aging syndromes caused by abnormally short telomeres, or shortened repetitive DNA sequences at the ends of chromosomes, may upend long-held scientific dogma and settle conflicting studies about how and whether short telomeres contribute to cancer risk.
With the combination of the drugs Venetoclax and 5-Azacitidine, a new, effective and more tolerable alternative to chemotherapy for the treatment of AML has been available for several years. But for some patients, the drug combination does not work.
Unlike other forms of blood cancer, acute myeloid leukemia (AML) cannot currently be treated with CAR-T cell immunotherapy.
People with a third copy of chromosome 21, known as trisomy 21, are at high risk of developing Acute Myeloid Leukaemia (AML), an aggressive form of blood cancer.
When Deb Horning's youngest daughter was 5, she got her measles, mumps, and rubella shot like many other kindergartners. But unlike many other moms, Horning had to stay away from her daughter for a week after the shot.
Pediatric acute myeloid leukemia or pAML is a childhood blood cancer, one that has proved confounding to clinicians and researchers, with a high relapse rate and relatively few identified genetic mutations (compared to the adult version) that might explain its cause.